12 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Indian pharmaceutical company based in Bangalore, Jubilant Biosys has said that the US Food and Drug Administration (FDA) has approved the novel molecule for clinical trials to treat prostate cancer.
"The FDA acceptance of our investigational new drug relates to the new molecule targeting prostate cancer. Approval of our filing paves way for the next stage of development and clinical trials later this year," Mr Subirkumar Basak, president of Jubilant drug discovery services, said in a statement.
The drug trials will be conducted in collaboration with US-based Endo Pharmaceuticals. "Being at the forefront of pharmaceutical, life sciences and healthcare innovation, we pursue our goal to enable affordable healthcare to patients worldwide," Mr Basak added.
Further, Mr Sandeep Gupta, vice president of Endo's discovery and early development, said in a statement, "Our multi-target oncology collaboration with Jubilant, which began four years ago, is focused on developing therapies that address the unmet needs of cancer patients worldwide."